TY  - JOUR
AU  - Jeschke, Matthias
AU  - Ludwig, Johannes M
AU  - Leyh, Catherine
AU  - Pabst, Kim M
AU  - Weber, Manuel
AU  - Theysohn, Jens M
AU  - Lange, Christian M
AU  - Herrmann, Ken
AU  - Schmidt, Hartmut H-J
AU  - Jochheim, Leonie S
TI  - Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.
JO  - Cancers
VL  - 15
IS  - 17
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2023-01852
SP  - 4274
PY  - 2023
AB  - Recommended treatment options for advanced-stage hepatocellular carcinoma (HCC) include systemic therapy (ST) and trans-arterial radioembolization (TARE) with Yttrium-90 (Y90). Before the approval of immune-checkpoint inhibitors, a similar safety profile was reported for TARE and ST with tyrosine kinase inhibitors (TKI). However, whole-liver treatment and underlying cirrhosis were identified as risk factors for potentially lethal radioembolization-induced liver disease (REILD). Therefore, the safety and efficacy of TARE and ST with atezolizumab/bevacizumab were compared in patients with advanced HCC involving at least both liver lobes in a retrospective real-world cohort. In total, 74 patients with new or recurrent advanced-stage HCC (BCLC stage B/C) were included if treated with either bilobar TARE (n = 33) or systemic combination therapy with atezolizumab plus bevacizumab (n = 41). Most patients had compensated liver function (90.5
KW  - ALBI (Other)
KW  - REILD (Other)
KW  - Yttrium-90 (Other)
KW  - atezolizumab (Other)
KW  - bevacizumab (Other)
KW  - hepatocellular carcinoma (Other)
KW  - hepatotoxicity (Other)
KW  - immune checkpoint inhibitors (Other)
KW  - radioembolization (Other)
KW  - systemic treatment (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37686549
C2  - pmc:PMC10486761
DO  - DOI:10.3390/cancers15174274
UR  - https://inrepo02.dkfz.de/record/282726
ER  -